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Purpose: To investigate the efficacy of  vascular endothelial growth
factor-specific (VEGF) monoclonal antibodies in the treatment of cho-
roidal neovascularization secondary to age-related macular degeneration
(AMD) that does not extend beneath the foveal center (nonsubfoveal
CNV). Methods: The study design was a retrospective chart review of
consecutive patients over a two-month period under active treatment
with bevacizumab and/or ranibizumab for neovascular AMD. Patients
with neovascularization within the macula that did not extend beneath
the center of the foveal avascular zone, along with at least one large
drusen (≥125 µ) or many intermediate size (63-124 µ) drusen were
included. Best corrected Snellen visual acuity and optical coherence
tomography (OCT) analysis of the central macular thickness was recor-
ded for each visit. Serial injections of bevacizumab and/or ranibizumab
were administered until there was resolution of subretinal fluid clinically
or by OCT. Data over the entire follow-up period were analyzed for
overall visual acuity and OCT changes. All patients had follow-up
since diagnosis of at least 6 months (mean=9.6 months). Results: Of the
thirteen included patients, eleven had reduction of retinal thickening
in the area involved by the CNV. The remaining two patients did not
have OCT data available but had no fluid or activity on clinical exa-
mination at last follow-up. One patient (8%) lost one line of vision; one
(8%) remained stable, and eleven (84%) gained one or more lines of
visual acuity. Three patients (23%) gained three or more lines. The
average treatment outcome for all patients was a gain of 1.7 ± 1.3 lines
of Snellen acuity. Both therapeutic agents were effective, with an average
gain of 1.6 ± 0.6 lines for patients treated with bevacizumab, 1.5 ± 1.9
lines gained for patients treated with ranibizumab and 2.5 ± 0.7 lines
gained in the two patients who received both agents over the course
of their treatment. Conclusions: The use of intravitreal anti-VEGF
agents for nonsubfoveal CNV in AMD is effective. Our results are com-
parable to published results from large-scale trials of anti-VEGF therapy
for subfoveal CNV. Our data support the idea that bevacizumab or
ranibizumab appear to be the treatment of choice for AMD patients with
nonsubfoveal CNV.
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 INTRODUCTION
Landmark studies have shown that the vascular endothelial
growth factor-specific (VEGF) monoclonal antibodies beva-
cizumab and ranibizumab are currently the best treatments
for patients with age-related macular degeneration (AMD)
and subfoveal choroidal neovascularization (CNV)(1-6). Except
for a single case report, the studies reported on patients whose
neovascularization extended beneath the center of the foveal
avascular zone(7).
The Macular Photocoagulation Studies showed that laser
photocoagulation was effective in reducing vision loss in pa-
tients with extrafoveal CNV (≥200 µm from the foveal center)
and juxtafoveal CNV (1-199 µm from the foveal center), but
the effect was limited to eyes with classic CNV lesions(8-11).
Problems with thermal laser treatment include damage to the
fovea and a high recurrence rate of CNV after treatment. Thermal
laser treatment can however potentially eradicate CNV, pre-
venting the need for repeated injections of a VEGF inhibitor.
Evidence for the use of PDT for the treatment of extrafoveal and
juxtafoveal CNV associated with AMD has also been publi-
shed, but is limited and has had highly variable results(12-15).
AMD patients with non-subfoveal CNV need prompt treat-
ment to avoid macular damage from fluid, hemorrhage, or scar-
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Figure 2 - (A) Fluorescein angiogram of study patient number 1 with classic extrafoveal CNV nasal to fovea (large arrow) in eye with atrophy
temporally (small arrow);  (B) Intraretinal fluid demonstrated by OCT prior to treatment; (C) OCT of same macular cross-section during treatment
 with ranibizumab demonstrating resolution of intraretinal fluid
Figure 1 - (A) Extrafoveal CNV, patient number 6;  (B) Juxtafoveal CNV, patient number 13
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ring from extension of the CNV into the fovea. Anti-VEGF
therapy offers the promise of effectively treating the neovas-
cular process while causing less damage than thermal laser.
Herein we present data from a series of patients with AMD
and vision loss from CNV that did not extend beneath the fovea
who were treated with bevacizumab and/or ranibizumab. We
compare these results with those from the Macular Photocoa-
gulation Studies.
METHODS
This study was approved by the Human Subjects Review
Committee of The University of Iowa Hospitals and Clinics.
Patients were collected from the practice of Dr. James Folk at
The University of Iowa. Every patient under active treatment
with either bevacizumab or ranibizumab for neovascular AMD
during the consecutive two month period from May 2008 to
June 2008 was potentially eligible. A retrospective chart review
was performed for all included patients. Fundus fluorescein
angiography (FFA) obtained at the time of initial presentation
was reviewed to confirm the diagnosis of AMD and to deter-
mine if the choroidal neovascularization extended beneath
the center of the fovea. Inclusion criteria included neovascu-
larization within the macula that did not extend beneath the
center of the foveal avascular zone (FAZ), along with at least
one large drusen (≥125 µ) or many intermediate size (63-124 µ)
drusen. Specific exclusion criteria included: geographic atro-
phy of the RPE that involved the fovea, fundus changes com-
patible with myopic degeneration, angioid streaks, chorio-
retinal scars in the macula which could indicate choroidal in-
flammatory disease, or history of any previous treatment for
CNV or any other retinal disease in the treatment eye.
The distance of the closest point of either the occult or
classic neovascularization to the center of the FAZ was measu-
red in microns using software on the digital photographic
system. In general a mid-phase image of the angiogram was used
when the neovascularization was completely filled but had
not yet leaked sufficiently to obscure its margins. Using criteria
from the MPS, choroidal neovascularization was considered
to be extrafoveal if its closest point did not extend closer than
200 µ to the center of the FAZ, and was classified as juxtafo-
veal if the closest point was closer than 200 µ to the center but
did not extend under the center of the FAZ. The determination
of whether the neovascularization was predominantly classic
or occult was made using previously reported criteria(12).
Patients were examined at 4-8 week intervals. At each visit,
best corrected Snellen visual acuity was measured and Stratus
optical coherence tomography (OCT) was performed and eva-
luated for the presence of intraretinal or subretinal fluid. The
central macular thickness as determined by OCT was recorded.
Repeat injections were performed until no subretinal or intra-
retinal fluid was seen on the OCT, at which time they were
considered an “anatomic success.” Two of the thirteen patients
were not followed with OCT imaging but instead by their
symptoms, visual acuity, and careful examination of the ma-
cula. Per our customary practice to prevent recurrence, all
patients were treated with additional injections even after they
exhibited resolution of subretinal fluid but the treatment
interval was gradually extended to up to 6 months. All patients
had at least 6 months of follow-up since diagnosis, and the mean
total follow-up time was 9.6 months.
RESULTS
The review resulted in 13 patients who met the criteria, none
of whom were excluded. Mean patient age was 81 (±6.8) years
(Table 1). Seven patients had classic lesions, three had occult
and three predominately occult CNV. Of the 13 patients, nine
(69%), had extrafoveal CNVand four, (31%), had juxtafoveal
CNV.
Seven patients were initially treated with an intravitreal
injection of 1.25 mg bevacizumab and six were treated initially
with 0.5mg of ranibizumab. Two of the thirteen patients recei-
ved both agents at different points over the course of their treat-
ment. Mean visual acuity at the time of diagnosis was 20/60
(logMAR 0.5, ± 0.28).
Table 1. Baseline characteristics, follow-up, and final treatment outcomes
Extrafoveal CNV Juxtafoveal CNV All study patients
(n=9) (n=4) (n=13)
Average age 81 ± 7 82 ± 8 81 ± 7
Males 3 2 5
Females 6 2 8
Mean baseline acuity, logMAR 0.4 ± 0.18 (20/50) 0.7 ± 0.4 (20/100) 0.5 ± 0.28 (20/60)
Mean CMT*, microns 320 ± 107 293 ± 30 311 ± 86
Mean follow-up, months 9.7 ± 6.1 9.5 ± 3.9 9.6 ± 5.4
Mean # injections 4.7 ± 2.6 5.5 ± 2.6 4.9 ± 2.6
Mean OCT change*, microns  -90 ± 78  -57 ± 53  -78 ± 69
Mean final acuity, logMAR 0.17 ± 0.08 (20/30) 0.5 ± 0.14 (20/60) 0.3 ± 0.18 (20/40)
Mean acuity change, Snellen lines  +1.7 ± 1.2  +1.8 ± 1.7  +1.7 ± 1.3
*= central macular thickness as determined by Stratus OCT. Two patients in the extrafoveal group did not have OCT data available
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Follow-up ranged from 6-24 months (Mean=9.6). The re-
sults were determined from data collected at the last visit. The
total number of injections averaged 5 (±2.6). Eleven patients
had reduction of retinal thickening in the area involved by the
CNV and the average central macular thickness reduction after
treatment was 78 ± 69 microns. The other two patients who did
not have OCT data had no fluid or activity on clinical exami-
nation. No patient had increased central macular thickness
on OCT as of the last follow-up.
At the final follow-up visit, one patient (8%) had lost one
line of vision since the beginning of treatment; one (8%) had
remained stable, and eleven (84%) had gained one or more
lines of visual acuity (Table 2). Three patients (23%) gained
three or more lines. The average treatment outcome for all
patients was a gain of 1.7 ± 1.3 lines of Snellen acuity (Table 1,
2). Both therapeutic agents were effective, with an average
gain of 1.6 ± 0.6 lines for patients treated with bevacizumab,
1.5 ± 1.9 lines gained for patients treated with ranibizumab and
2.5 ± 0.7 lines gained in the two patients who received both
agents over the course of their treatment. This study was too
small to calculate statistically significant differences in treat-
ment outcomes between the extrafoveal and juxtafoveal
groups, the different CNV lesion types, or between the thera-
peutic agent used. However, results in all subgroups appeared
Table 3. Comparison of visual acuity change in study patients to MARINA and ANCHOR trials of bevacizumab for classic and occult subfoveal CNV
ANCHOR MARINA Study patients Study patients All study
                (Classic)*             (Occult)*             Classic (n=6)          Occult (n=7)          patients
Baseline visual acuity >20/200, <20/40 73% 72% 57% 83% 69%
Patients with ≤ 3 lines lost 96% 95% 100% 100% 100%
Patients with ≥ 3 lines gained 40% 34% 14% 17% 23%
Patients with final VA 20/40 or better 49% 40% 71% 67% 69%
Mean acuity change  + 2.1 lines  + 1.3 lines  +1.7 lines  +1.7 lines  +1.7 lines
One line of visual acuity assumed as equivalent to five ETDRS letters for purpose of study comparison; *= data from 0.5 mg ranibizumab treatment group
similarly favorable. All of the 13 patients responded to treat-
ment evident by resolution of retinal or subretinal edema on
OCT, visual improvement or clinical resolution of hemorrhage
and edema associated with CNV.
DISCUSSION
The results of this small series of nonsubfoveal CNV in
patients with AMD are similar to the visual results of the large
MARINA and ANCHOR trials for subfoveal CNV (Table 3).
As demonstrated in these trials, both occult and classic neovas-
cularization responded to anti-VEGF therapy in our patients.
A slightly greater proportion of our patients had 20/40 or better
acuity, probably because there was no subfoveal scarring. We
also attempted to compare our results with the MPS studies
which used argon laser to treat extrafoveal CNV and krypton
red laser to treat juxtafoveal CNV (Table 4). While our results
seem favorable, a comparison of different patient groups from
different studies and different decades is impossible to inter-
pret in a scientific manner. A prospective, randomized controlled
trial is needed to confirm our results.
Bevacizumab and/or ranibizumab was successful at control-
ling the CNV in all of our study patients. Only one of the 13
patients in this study lost one line of vision, one remained stable,
Table 2. Individual data for all study patients
Patient CNV Type VA at OCT at Treatment Number of Follow-up Final VA Final VA
 location diagnosis diagnosis* injections (months) (Snellen) (change)
              (Snellen)     (microns)                                    (lines)
  1 Extrafoveal Classic 20/50 296 Ranibizumab  5  9 20/25 (+3)
  2 Extrafoveal Classic 20/40 n/a Bevacizumab  3  5 20/25 (+2)
  3 Extrafoveal Occult 20/50 278 Bevacizumab  3  5 20/30 (+2)
  4 Extrafoveal Classic 20/50 281 Bevacizumab  3  6 20/40 (+1)
  5 Extrafoveal Pred. Occult 20/60 432 Both  3  5 20/30 (+3)
  6 Extrafoveal Classic 20/25 247 Ranibizumab  5 14 20/30 (-1)
  7 Extrafoveal Classic 20/50 n/a Bevacizumab  3  9 20/30 (+2)
  8 Extrafoveal Occult 20/50 506 Both 11 24 20/30 (+2)
  9 Extrafoveal Occult 20/40 206 Ranibizumab  6 10 20/30 (+1)
10 Juxtafoveal Pred. Occult 20/80 309 Ranibizumab  9 15 20/60 (+2)
11 Juxtafoveal Classic 20/60 310 Bevacizumab  3  8 20/50 (+1)
12 Juxtafoveal Pred. Occult 20/50 248 Ranibizumab  4  6 20/50 (0)
13 Juxtafoveal Classic 20/400 303 Ranibizumab  6  9 20/100 (+4)
*= central macular thickness as determined by Stratus OCT
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Table 4. Comparison of visual acuity change in study patients to MPS data for extrafoveal and juxtafoveal CNV
Visual acuity MPS-SMDS (extrafoveal)** MPS-AMDS-K (juxtafoveal)*** Study patients
Increase or no change* 57% 26% 100%
2-5 line decrease 28% 24% 0%
>5 line decrease 15% 50% 0%
*= increase or no change as defined by MPS is ≤ 1 line of acuity lost; **= MPS-SMDS data for patients with minimum 6-month follow up; ***= MPS AMDS-K data for
patients with 3 year follow-up
and the other 11 had visual improvement. Seventy percent had
20/40 or better vision at last follow-up. Based on the results of
this small series, bevacizumab or ranibizumab appear to be the
treatment of choice for AMD patients with nonsubfoveal CNV.
The exception could be the patient who has a CNV far from
the fovea and who does not want repeated intravitreal injec-
tions. Our results are encouraging and deserve further inves-
tigation with a larger prospective trial.
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RESUMO
Objetivo: Investigar a eficácia dos anti-angiogênicos ranibi-
zumab e bevacizumab injetados intravítreo, no tratamento de
pacientes com neovascularização de coróide extrafoveal em
degeneração macular relacionada à idade. Métodos: Foram
avaliados 13 pacientes com neovascularização de coróide ex-
trafoveal em degeneração macular relacionada à idade do
Setor de Retina e Vítreo do Departamento de Oftalmologia da
Universidade de Iowa, Estados Unidos, que foram tratados
por meio de injeção vítrea de ranibizumab e bevacizumab se-
paradamente, em um período de dois anos. Após as injeções
iniciais os pacientes foram acompanhados por exames de OCT
e as injeções foram repetidas com 4 a 8 semanas dependendo
da presença de líquido sub-retiniano e macular. Resultados:
Doze pacientes tiveram ganhos de linhas de visão se compara-
dos com a visão antes do tratamento. Onze pacientes tiveram
redução do espessamento retiniano na área envolvida pelo
CNV e diminuição e resolução do espessamento macular na
sua visita final de avaliação. Um paciente (8%) perdeu uma
linha de visão se comparado à visão prévia ao tratamento.
Pacientes tratados com o ranibizumab tiveram em média 2,5 ±
0,7 ganhos de linhas de visão. Pacientes tratados com beva-
cizumab tiveram em média 1,6 ± ganhos de linhas de visão.
Conclusão: No tratamento de pacientes com a neovascula-
rização de coróide extrafoveal em degeneração macular rela-
cionada à idade, a injeção vítrea de ranibizumab ou bevaci-
zumab é efetiva e pode ser a opção de escolha.
Descritores: Neovascularização coroidal/quimioterapia; De-
generação macular/quimioterapia; Anticorpos monoclonais;
Inibidores da angiogênese; Acuidade visual
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